Medicine Overview

Adult Dose

Clinical InformationAdministration Information
Indication: Benign Prostatic Hyperplasia
Age: Adult
Dose: Capsule – 5 mg/5 mg
Frequency: once daily by mouth
Duration: up to 26 weeks
Note: Indicated to initiate treatment for signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Not recommended for greater than 26 weeks; incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and incremental benefit greater than 26 weeks is unknown.
Indication: Benign Prostatic Hyperplasia
Age: Adult
Condition: Mild-to-moderate hepatic impairment (Child-Pugh A or B)
Dose: Capsule – 5 mg/5 mg
Note: Caution; finasteride extensively metabolized in liver.

Child Dose

Clinical InformationAdministration Information
Age: Child
Dose: Form – Not specified
Note: No approved pediatric dosage available

Renal Dose

Clinical InformationAdministration Information
Condition: Renal impairment CrCl less than 50 mL/min or on hemodialysis
Dose: No dose recommendation
Note: Not recommended; increased tadalafil exposure (AUC), limited clinical experience, and inability of dialysis to influence clearance
Administration

Administer finasteride and tadalafil orally as a single fixed-dose combination capsule once daily at approximately the same time for up to 26 weeks. The medication must be taken on an empty stomach to ensure proper absorption. Capsules should be swallowed whole; do not crush or open them, especially since finasteride can be absorbed through the skin and is hazardous to pregnant women or those planning pregnancy. Use with caution in patients with mild to moderate hepatic or renal impairment, as dosage adjustments for the individual components may be necessary. It is contraindicated in patients using any form of organic nitrates or guanylate cyclase stimulators due to the risk of severe hypotension. Safety and efficacy have not been established in pediatric populations, and its use is restricted to adult men.

Side Effect

Drug Interaction

Details coming soon

Disease Interaction

Details coming soon

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.